Advertisement

Topics

PubMed Journals Articles About "RFVIIa Prophylaxis In Children With Hemophilia A And Inhibitors" RSS

21:45 EDT 19th August 2018 | BioPortfolio

RFVIIa Prophylaxis In Children With Hemophilia A And Inhibitors PubMed articles on BioPortfolio. Our PubMed references draw on over 21 million records from the medical literature. Here you can see the latest RFVIIa Prophylaxis In Children With Hemophilia A And Inhibitors articles that have been published worldwide.

More Information about "RFVIIa Prophylaxis In Children With Hemophilia A And Inhibitors" on BioPortfolio

We have published hundreds of RFVIIa Prophylaxis In Children With Hemophilia A And Inhibitors news stories on BioPortfolio along with dozens of RFVIIa Prophylaxis In Children With Hemophilia A And Inhibitors Clinical Trials and PubMed Articles about RFVIIa Prophylaxis In Children With Hemophilia A And Inhibitors for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of RFVIIa Prophylaxis In Children With Hemophilia A And Inhibitors Companies in our database. You can also find out about relevant RFVIIa Prophylaxis In Children With Hemophilia A And Inhibitors Drugs and Medications on this site too.

Showing "rFVIIa Prophylaxis Children With Hemophilia Inhibitors" PubMed Articles 1–25 of 10,000+

Treatment Regimens with Bypassing Agents in Patients with Hemophilia A and Inhibitors: A Survey from the Italian Association of Hemophilia Centers (AICE).

The development of neutralizing antibodies (inhibitors) against infused factor VIII currently represents the main complication of replacement therapy in patients with severe hemophilia A. Inhibitors, indeed, particularly high-titer inhibitors (>5 BU/mL), greatly complicate the management of bleeding, exposing patients to an increased morbidity and mortality risk, thus representing a significant burden for physicians of Hemophilia Treatment Centers (HTCs). Although bypassing agents (i.e., activated prothromb...


Optimization of prophylaxis for hemophilia A.

Prophylactic injections of factor VIII reduce the incidence of bleeds and slow the development of joint damage in people with hemophilia. The aim of this study was to identify optimal person-specific prophylaxis regimens for children with hemophilia A.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors.


Emicizumab Prophylaxis in Hemophilia A with Inhibitors.

Emicizumab Prophylaxis in Hemophilia A with Inhibitors.

Modified Primary Prophylaxis in Previously Untreated Patients With Severe Hemophilia A in Iran.

Recently the low-dose tailoring method of primary prophylaxis has been introduced for previously untreated patients with hemophilia A.

Inhibitors in Hemophilia B.

Hemophilia B (HB) is an X-linked bleeding disorder caused by deficiency of factor IX (FIX). Patients with the severe form (FIX

Hemlibra's Remarkable Efficacy A Beacon For Hemophilia Patients.

Hemlibra demonstrates how far antibody science has progressed. Genentech's drug, approved late last year, connects two clotting factors to prevent the devastating bleeds in hemophilia patients with inhibitors. The high price may be offset by avoided costs in patients with factor VIII inhibitors.

Value of prophylaxis vs on-demand treatment: Application of a value framework in hemophilia.

Therapeutic advances over the past 30 years have led to longer life expectancy and improved quality of life (QOL) for persons with hemophilia. Access to innovative therapy may be compromised if treatment decisions are driven solely by cost. New strategies are needed to assess true therapeutic values, along with financial cost, as physicians, policymakers, payers and manufacturers work together to improve patient care.

Safety of Dexamethasone for Nausea and Vomiting Prophylaxis in Children Receiving Hematopoietic Stem Cell Transplantation.

Many children undergoing hematopoietic stem cell transplantation (HSCT) experience chemotherapy-induced nausea and vomiting (CINV) despite receiving prophylaxis. Guideline-consistent CINV prophylaxis includes dexamethasone, but uncertainty with regard to safety potentially limits the use of dexamethasone in children. We describe immediate adverse events (AEs) attributable to dexamethasone given for CINV prophylaxis to children during HSCT conditioning.

Perioperative haemostasis in children with haemophilia and inhibitors during central venous catheter surgery: The Karolinska model.

Bypassing Agents for Bleeding Prophylaxis in Hemophilia B: A Clinical Conundrum?

Correction: Optimization of prophylaxis for hemophilia A.

[This corrects the article DOI: 10.1371/journal.pone.0192783.].

High Rates of Prescribing Antimicrobials for Prophylaxis in Children and Neonates: Results From the Antibiotic Resistance and Prescribing in European Children Point Prevalence Survey.

This study was conducted to assess the variation in prescription practices for systemic antimicrobial agents used for prophylaxis among pediatric patients hospitalized in 41 countries worldwide.

Micafungin antifungal prophylaxis in children undergoing HSCT: can we give higher doses, less frequently? A pharmacokinetic study.

Micafungin has a distinct advantage for antifungal prophylaxis in HSCT owing to its better safety profile, specifically in terms of hepatic and renal toxicity. In children, prophylactic micafungin is given as either 1 mg/kg every day or 3 mg/kg every other day.

Bleeding-related hospitalization in patients with von Willebrand disease and the impact of prophylaxis: Results from national registers in Sweden compared with normal controls and participants in the von Willebrand Disease Prophylaxis Network.

Patients suffering from von Willebrand disease (VWD) have a variety of bleeding symptoms and require both outpatient care for treatment and, in more severe cases, hospitalization.

Preventing or Eradicating Factor VIII Antibody Formation in Patients with Hemophilia A: What Can We Learn from Other Disorders?

Eradication of factor VIII (FVIII) specific neutralizing antibodies (also known as inhibitors) by the traditional method of immune tolerance induction (ITI) is costly and unsuccessful in one out of three patients. Furthermore, effective inhibitor prevention strategies are presently lacking. An overview is given in this narrative review of antidrug antibody prevention or eradication strategies that have been used in disorders beyond hemophilia A, with the aim of analyzing what we can learn from these strateg...

Pharmacokinetics of posaconazol in the prophylaxis and treatment of invasive fungal infection in immunocompromised children in a pediatric hospital.

Background There is no consensus on the optimal dosage use of posaconazole (PSC) for invasive fungal infection (IFI) in pediatric patients and normally it is adjusted with drug levels (DLs) ≥ 0.7 μg/ml and ≥ 1.25 μg/ml for prophylaxis and treatment, respectively. Objective To describe the experience of monitoring DLs of PSC in immunocompromised pediatric patients with IFI and to determine if the recommended doses reach CP effective in prophylaxis (≥ 0.7 μg/mL) and treatment (≥ 1.25 μg/mL). Metho...

Antibiotic prophylaxis in neutropenic children with acute leukemia: do the presently available data really support this practice?

Antibiotics are frequently administered for prophylaxis of fever in neutropenic children with cancer. This strategy is mainly derived from adults' data, and various pediatric studies evidenced the effectiveness of antibiotics (e.g. fluorquinolones) in the prevention of febrile neutropenia. However, only two pediatric randomized, double blind, placebo-controlled trials have been performed, with a total of 262 leukemic children enrolled, and no other one was ever powered for analyzing effectiveness over other...

Impact of target joint and FVIII inhibitor οn bone properties in children with haemophilia A: A peripheral quantitative computed tomography study.

Haemophilic children are prone to low bone mass accrual.

Prophylactic bypassing agent use before and during immune tolerance induction in patients with haemophilia A and inhibitors to FVIII.

The development of high-titre inhibitory antibodies (inhibitors) against factor VIII (FVIII) remains a challenge in the management of patients with haemophilia A (HA). Patients with high-titre inhibitors are more likely to experience uncontrolled bleeding, physical disability from chronic arthropathy and premature death compared with those without this complication. Immune tolerance induction (ITI), utilizing repeated infusions of FVIII, is an effective therapeutic approach to eliminating inhibitory antibod...

Impact of Hemophilia B on Quality of Life in Affected Men, Women, and Caregivers - Assessment of Patient-Reported Outcomes in the B-HERO-S Study.

Health-related quality of life (HRQoL) is impaired in patients with hemophilia, however the impact in mild/moderate hemophilia B and affected women is not well characterized.

Antibiotic Prophylaxis for Pyloromyotomy in Children: An Opportunity for Better Stewardship.

Surgical site infection is very uncommon after pyloromyotomy in children, and it is considered a "clean" procedure under the traditional wound classification system. This study aims to investigate prophylactic antibiotic administration for pyloromyotomy among children's hospitals in the USA.

Risk factors for inhibitor development in severe hemophilia a.

Although significant advances in hemophilia treatment have improved patient outcomes and quality of life, one of the greatest complications in severe hemophilia A is the development of anti-Factor VIII (FVIII) antibodies that inhibit FVIII activity in almost 30% of previously untreated patients (PUPs). Inhibitors make very difficult the management of patients and increase their morbidity and mortality reducing drastically their quality of life. Numerous studies have investigated the mechanisms leading to th...

Itraconazole Dosing and Drug Monitoring at a Tertiary Children's Hospital.

Itraconazole is a broad-spectrum antifungal agent used for prophylaxis and treatment of fungal infections in immunocompromised children. Achieving the recommended target serum itraconazole trough concentration of ≥0.5 mg/L is challenging in children due to variation in itraconazole pharmacokinetics with age. We studied itraconazole use and treatment outcomes in a tertiary children's hospital.


Advertisement
Quick Search
Advertisement
Advertisement